Microdosing — consuming quantities of a psychoactive substance below the threshold of perceptible intoxication — has attracted mainstream attention through the psychedelic research renaissance. Cannabis microdosing follows similar principles: using THC at doses (typically 1–5mg) too small to cause obvious impairment while potentially providing therapeutic benefits.
The Biphasic Dose-Response
The scientific basis for microdosing rests on what pharmacologists call a biphasic dose-response relationship. Multiple studies have documented that low-dose THC reduces anxiety while higher doses increase it — a phenomenon mediated by different CB1 receptor populations in the amygdala and prefrontal cortex [1]. The same biphasic pattern appears in pain research, where Wallace et al. found low doses reduced pain sensitization and high doses paradoxically increased it.
A 2017 study by Chiurchiù et al. in Neurotherapeutics documented that low-dose cannabinoid exposure upregulates endocannabinoid tone, while high doses suppress it through receptor downregulation [2]. This provides a mechanistic explanation for why heavy daily users often report diminishing returns — a phenomenon well-documented in clinical surveys.
Clinical Evidence
Formal microdosing clinical trials remain sparse. The strongest data comes from pain research: a 2012 study found that a vaporized cannabis dose of 1.5–3.5% THC significantly reduced neuropathic pain with minimal cognitive impairment, while a 9% THC dose produced greater impairment without proportionally greater analgesia [3].
Key Evidence Points
- Biphasic dose-response: low-dose THC reduces anxiety; high-dose THC increases it [1]
- Low-dose cannabinoid exposure upregulates endocannabinoid tone; high doses suppress it [2]
- 1.5–3.5% THC vaporized provided neuropathic pain relief with minimal cognitive impairment [3]
- No published RCT has specifically studied microdosing as a defined intervention
- Tolerance development at low doses appears slower than with full intoxicating doses
Citations
- Pacher P, Bátkai S, Kunos G. The Endocannabinoid System as an Emerging Target of Pharmacotherapy. Pharmacol Rev. 2006;58(3):389–462. PubMed 16968947
- Chiurchiù V, van der Stelt M, Centonze D, Maccarrone M. The endocannabinoid system and its therapeutic exploitation in multiple sclerosis. Nat Rev Neurol. 2018;14(1):9–22.
- Wilsey B, Marcotte T, Deutsch R, et al. Low-Dose Vaporized Cannabis Significantly Improves Neuropathic Pain. J Pain. 2013;14(2):136–148. PubMed 23237736